Form 4: Cencora Executive Chairman Steven Collis Exercises Options and Sells Shares Under Pre-Arranged Plan

Cencora's Executive Chairman, Steven H. Collis, executed a pre-arranged transaction on June 24, 2025, involving the exercise of stock options and the subsequent sale of common stock.

Summary

• Steven H. Collis, Executive Chairman and Director of Cencora, Inc. (COR), reported transactions on June 24, 2025.
• Mr. Collis acquired 12,579 shares of Cencora Common Stock by exercising non-qualified stock options at a price of $86.09 per share.
• Concurrently, he disposed of 14,579 shares of Cencora Common Stock at a price of $292.62 per share.
• The sale of shares was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Collis on November 25, 2024.
• Following these transactions, Mr. Collis directly beneficially owns 311,912.665 shares of Cencora Common Stock and 113,206 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While there's an insider sale, it's under a pre-arranged 10b5-1 plan, which mitigates negative perception. The executive realized significant gains from option exercise, which is a positive for the individual and reflects the stock's appreciation.

Positives

• The exercise of stock options indicates the executive is realizing value from previously granted equity compensation.
• The sale price of $292.62 per share is significantly higher than the exercise price of $86.09, indicating a substantial gain for the executive.
• The transaction was conducted under a Rule 10b5-1 trading plan, which suggests a pre-planned and routine liquidity event rather than a reaction to new, non-public information.

Negatives

• The sale of shares by an executive, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, although this is mitigated by the pre-planned nature.
• The number of shares sold (14,579) is slightly higher than the number of shares acquired through option exercise (12,579), resulting in a net reduction of direct common stock holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction filing (Form 4) for an executive at Cencora, Inc., a major player in the pharmaceutical distribution and healthcare services industry. Such filings are common and typically reflect pre-planned liquidity events or compensation-related activities rather than significant shifts in company strategy or industry trends.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all publicly traded companies in the U.S.
• The reported transactions, involving the exercise of stock options and subsequent sale of shares under a Rule 10b5-1 plan, are common practices for executives managing their equity compensation and personal finances.
• There are no specific comparable companies or projects mentioned in this filing to assess against industry benchmarks.

Stakeholder Impact

• Shareholders: The net sale of shares by a key executive could be viewed neutrally or slightly negatively, though the 10b5-1 plan mitigates concerns. The transaction itself does not directly impact company operations or financial performance.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Cencora, COR, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Steven H. Collis, Executive Compensation, Rule 10b5-1 Plan